CRE caused 2.2% of all BSIs and 4.7% of Gram-negative BSIs in neutropenic patients.
Multiple antibiotics, steroids and a prior CRE culture were CRE BSI risk factors.
Patients with CRE BSI had a 2–3-day delay until receipt of CRE-active therapy.
The CRE BSI-related mortality rate was 51%, with a median of 4 days until death.
New strategies are needed to mitigate this threat in this vulnerable population.